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•Seven proteins differ between two reovirus stocks. 
 
•Differences in sensitivity to interferon depends on both µ2 and λ2 proteins. 
 
•Differences in interferon induction depends on both µ2 and λ1 proteins. 
 
•Sensitivity to interferon and induction of interferon can be partly separated. 
 







In the course of previous works, it was observed that the virus laboratory stock (T3DS) differs in 
sequence from the virus encoded by the ten plasmids currently in use in many laboratories 
(T3DK), and derived from a different original virus stock. Seven proteins are affected by these 
sequence differences. In the present study, replication of T3DK was shown to be more sensitive to 
the antiviral effect of interferon. Infection by the T3DK virus was also shown to induce the 
production of higher amount of β and α-interferons compared to T3DS. Two proteins, the µ2 and 
λ2 proteins, were found to be responsible for increased sensitivity to interferon while both µ2 and 
λ1 are responsible for increased interferon secretion. Altogether this supports the idea that 
multiple reovirus proteins are involved in the control of induction of interferon and virus 
sensitivity to the interferon-induced response. While interrelated, interferon induction and 
sensitivity can be separated by defined gene combinations. While both µ2 and λ2 were 
previously suspected of a role in the control of the interferon response, other proteins are also 
likely involved, as first shown here for λ1. This also further stresses that due caution should be 








 In the last few years, it has been observed that so-called wild-type reovirus can slightly 
vary in sequence from one laboratory stock to the other, even if they are all referred to as type 3 
Dearing strain. This could result from random genetic drift or to different experimental 
conditions for virus growth. Isolation of single plaques, sometimes used as a routine procedure to 
avoid accumulation of non-infectious viral mutants upon virus propagation has also likely 
contributed to this situation. Variations between sequences of laboratory stocks are observed 
when comparing the few cases where complete sequences were reported from a given stock 
(Kobayashi et al., 2007; van den Wollenberg et al., 2012; Chakrabarty et al., 2014; 
Sandekian and Lemay, 2015a). Also, differences in phenotypic properties between virus stocks 
were observed in few cases (Yin et al., 2004; Coffey et al., 2006; Nygaard et al., 2013; Berard 
et al., 2015). These variations have led to the denomination of viral subtypes such as T3DC, 
T3DF, T3DH, T3DN, T3DK, T3DS and T3DW (Sandekian and Lemay, 2015a). 
 Previous work has shown that the viral stock encoded by the plasmids used in reverse 
genetics (herein referred to as T3D-Kobayashi, T3DK) do differ from the laboratory virus stock in 
7 out of 11 proteins (Sandekian and Lemay, 2015a). In the course of this previous work the 
laboratory wild-type virus stock (herein referred to as T3D-Sandekian, T3DS) was reconstructed 
by site-directed mutagenesis and reverse genetics, in order to allow comparisons with viral 
mutants derived from this laboratory stock. Although this aspect was not specifically mentioned 
in the previous publication, it was noticed that the reverse genetics virus (T3DK) is significantly 
more sensitive to interferon than T3DS. 
A plethora of viruses is presently considered as possible oncolytic viruses for cancer 
treatment as recently reviewed by many authors (Ilkow et al., 2014; Miest and Cattaneo, 2014; 
Pikor et al., 2015; Turnbull et al., 2015). Among these, reovirus is one of the most advanced in 
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clinical settings, being currently in phase III. It presents the advantage of exhibiting a natural 
tropism for cancer cells while being essentially nonpathogenic in adult humans (Kelly et al., 
2009; Harrington et al., 2010; Black and Morris, 2012; Clements et al., 2014; Chakrabarty 
et al., 2015). The interferon response often plays a role in determining the ability of a virus to 
discriminate between cancer cells, frequently exhibiting a reduced interferon response, and 
normal cells (Randall and Goodbourn, 2008; Naik and Russell, 2009; Kaufman et al., 2015). 
However, examples abound where interferon can still contribute to limiting oncolytic activity, as 
recently reviewed (Vaha-Koskela and Hinkkanen, 2014; Ebrahimi et al., 2017). The original 
model of reovirus oncolytic activity postulated that a decreased in the interferon-induced protein 
kinase PKR was responsible for the increased ability of Ras-transformed cells to allow reovirus 
replication resulting in cell lysis (Strong et al., 1998). Further work indicated that the defective 
interferon secretion of Ras-transformed cells favors cell-to-cell viral propagation in these cells 
compared to normal cells (Shmulevitz et al., 2010). It thus appears to be essential to gain a 
further understanding of the viral determinants that control induction of the interferon response 
and the sensitivity of different viral isolates to this response. This could possibly lead to better 
optimization of viral strains toward oncolytic activity, as many investigators believe to be 
possible, and as recently reviewed (Mohamed et al., 2015; Kemp et al., 2016). This is 
especially envisaged since the advent of plasmid-based reverse genetics to manipulate the viral 
genome (Lemay, 2011; van den Hengel et al., 2013; Stuart et al., 2017). In the present study, 
reverse genetics was thus used to introduce each of the T3DK gene in the T3DS genetic 
background, either separately or in different combinations, in order to determine which protein(s) 
is responsible for this difference in interferon response. 
While no single protein of T3DK in the T3DS background was sufficient to reconstitute 
the full phenotype of sensitivity observed in T3DK, a combination of µ2 and λ2 was shown to be 
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both necessary and sufficient. Also, as somewhat expected from previous studies by others 
(Zurney et al., 2009; Irvin et al., 2012), the µ2 protein was shown to be partly responsible for 
higher levels of interferon induction upon T3DK infection compared to T3DS. However, an 
unexpected finding is that λ1 is also responsible for the full level of induction observed. At least 




2. Materials and methods 
 
2.1. Cell lines and viruses 
 L929 mouse fibroblasts were originally obtained from the American type culture 
collection (ATCC® CCL-1™). The baby hamster kidney cell line (BHK) stably expressing the 
T7 RNA polymerase (BSR-T7 cells) has been described (Buchholz et al., 1999) and was a 
generous gift from the laboratory of Dr. John Hiscott (Lady Davis Research Institute, Montréal, 
Canada). Both cell lines were grown in minimal Eagle medium (MEM) with 5% fetal bovine 
serum. 
 Wild-type laboratory stock of reovirus type 3 (T3DS) was previously described 
(Sandekian and Lemay, 2015a,b) and was rescued by reverse genetics following introduction of 
the appropriate mutations in the plasmids encoding the wild-type virus from Dr. Terry 
Dermody’s laboratory (T3DK). Other viruses, harboring various combinations of genes from 
T3DK in the T3DS background were obtained by reverse genetics, as described below. 
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All virus stocks were routinely grown on L929 cells and virus titers determined by TCID50, as 
described (Danis and Lemay, 1993). In addition, since some assays used in the course of the 
work rely on similar cell-killing and lysis ability of the different viruses, serial binary dilutions of 
each virus was used to infect L929 cells in single wells of a 96-well plates. Cells were incubated 
for 4–5 days before being fixed and remaining cells stained with methylene blue, as previously 
described (Sandekian et al., 2013; Sandekian and Lemay, 2015a). 
 
2.2. Reovirus reverse genetics 
The plasmids corresponding to the 10 genes of reovirus serotype 3 Dearing, T3DK, under 
the transcriptional control of the T7 promoter were originally obtained from the laboratory of 
Dr. Terence Dermody (Vanderbilt University, Nashville, Tennessee) (Kobayashi et al., 2007). 
The recovery of the wild-type laboratory stock T3DS was achieved by first submitting each 
plasmid to site-directed mutagenesis for each of the gene segment differing between T3DS and 
T3DK. Plasmids were then used to recover infectious virus by the improved reverse genetics 
approach using transfection in BHK cells expressing the T7 RNA polymerase (Kobayashi et al., 
2010). Rescued viruses were propagated as described before (Brochu-Lafontaine and Lemay, 
2012; Sandekian and Lemay, 2015a,b).  
  
2.3. Determination of interferon sensitivity 
 Mouse type I β-interferon was obtained from PBL interferon source. Two different 
approaches were used to determine interferon sensitivity on mouse L929 cells. Decreased virus 
titer at near saturating concentration, 200 international units(IU)/ml, was measured by TCID50, as 
previously used. Similarly, interferon sensitivity to varying dilutions of interferon on L929 cells 
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was determined, also as before (Sandekian and Lemay, 2015a). Briefly, binary dilutions of 
interferon were prepared from 500 IU/ml in single wells of a 96-well plates seeded with L929 
cells. Cells were infected with the different viruses at a MOI of 0.05, incubated for 4–5 days 
before being fixed and stained with methylene blue. Remaining cell-retained stain was 
solubilized and quantitated, essentially as described before (Sandekian et al., 2013), using a Bio-
TEK microplate reader Elx800. Relative cell destruction was determined by comparison with 
mock-infected cells. 
 
2.4. Determination of interferon induction 
 Enzyme-linked immunosorbent assay (ELISA) was performed on different dilutions of 
mock-infected or infected cell culture medium to determine the concentration of either β-
interferon or all subtypes of α-interferon (Verikine mouse interferon beta and alpha ELISA kit, 
PBL Assay Science). Results from mock-infected cells were always below detection level. 





3.1. Generation and characterization of T3DS/T3DK monoreassortants. 
 The differences in sequence between the wild-type laboratory virus stock of reovirus 
serotype 3 Dearing T3DS (originally obtained from ATCC) and that of the serotype 3 Dearing 
recovered using the plasmid-based reverse genetics system, T3DK, were previously reported 
(Sandekian and Lemay, 2015a); for the sake of simplicity this information is repeated herein 
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(Table 1). A total of 24 nucleotide differences, 21 transitions and 3 transversions, were observed. 
These resulted in 12 amino acids changes in 7 different viral proteins. 
In a first set of experiments, each of these seven T3DK genes were separately used to 
replace their homologous gene in the T3DS background. The seven monoreassortant viruses were 
recovered and propagated with similar final titers. In parallel, in order to avoid discrepancies due 
to possible differences in cell-killing ability at the same multiplicity of infection, cells were 
infected with serial binary dilutions of the different viruses, as described in Materials and 
methods (section 2.1). All viruses had similar replication phenotype, as measured by this 
approach (data not shown). 
The infectious titers of the different viruses were then compared in the absence or 
presence of interferon at 200 IU/ml (Fig 1). Each virus exhibited resistance to interferon 
treatment similar to that of T3DS. Only viruses harboring the M1 gene (encoding the µ2 protein) 
and possibly the L2 gene (encoding the λ2 protein) were slightly more sensitive to interferon but 
far from the high sensitivity observed for T3DK. The different viruses were also examined at 
various interferon concentrations, as described in Materials and methods (section 2.3). Again, no 
single gene can reconstitute the full T3DK sensitivity phenotype and only M1 had an effect in this 
assay (data not shown). 
 
3.2. Introduction of different T3DK gene combinations in T3DS background 
 The previous results indicated that interferon sensitivity of T3DK depends on a 
combination of more than one gene, and suggested that at least M1 (encoding µ2) could be 
partially but not solely responsible. Results also suggested that at least one of the L genes is 
involved. Viruses harboring different gene combinations of T3DK in the T3DS background were 
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thus obtained and their sensitivity to interferon first examined by the TCID50 assay at 200 IU/ml 
of β-interferon (Fig. 2). 
In a first virus, the M2 gene (encoding µ1) and the S1 gene (encoding both σ1 and σ1s) 
were left aside since they were the least likely to be involved in the previous experiment; as 
expected, the three L genes with M1 and M3 were sufficient to recover the full sensitivity. A 
series of 4, 3 or 2 gene combinations were then examined. It appears that neither the two M genes 
(M1+M3) or the three L genes can reconstitute the phenotype. In contrast a combination of the 
three L genes with M1 (but not M3) reconstitutes the full sensitivity. When examining each of 
the L genes, the L2 gene together with M1 appears both necessary and sufficient while M1+L3 
had an effect but did not reconstitute the full phenotype. 
 The two most interesting combinations, namely M1+L2 and M1+L3, were thus further 
examined using various dilutions of interferon (Fig. 3), as described in Materials and methods. 
Again, in this assay, the M1+L2 combination showed a pattern of sensitivity very close to that of 
T3DK, thus confirming that these two genes are sufficient to reconstitute the full sensitivity 
phenotype. Interestingly, the M1+L3 combination did increase interferon sensitivity to a similar 
level at low interferon concentration but this effect was lost at the highest interferon 
concentrations, approaching that of T3DS. Furthermore, when cells were infected at low MOI in 
the presence of high interferon concentrations (125 IU/ml), the amount of infectious virus 
produced by the virus harboring the M1+L2 combination and T3DK were similarly affected. In 
contrast, the virus harboring the M1+L3 combination behave essentially as T3DS (data not 
shown). Altogether, the M1+L2 combination thus appears as the main determinant of interferon 
sensitivity of T3DK compared to T3DS. The contribution of L3 observed more easily at lower 
interferon concentrations will be further discussed below. 
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3.3. Induction of interferon by T3DK gene combinations in T3DS background 
To get a more complete understanding of the contribution of M1, L2 and L3 to the control 
of the interferon response, and to determine if their effect could be due to differences in induction 
of interferon, interferon induction following viral infection was next examined. This will also 
allow to verify if a direct correlation exists between induction of interferon consecutive to virus 
infection, and the sensitivity of the virus to interferon. Although this was not discussed in 
previous studies, a higher induction upon T3DK compared to T3DS infection was expected. In 
fact, amino acid 208 of T3DK µ2 protein is a serine (Table 1) previously shown to result in a 
decreased ability to control induction of interferon and of the interferon-induced response. In 
contrast, viruses with proline at this position, as in T3DS, were more able to repress the induction 
(Zurney et al., 2009; Stebbing et al., 2014). 
In the present study, the production of interferon at the protein level was directly 
measured in the culture medium of infected cells using commercially available ELISA assays. 
This confirmed a close to thousandfold higher β-interferon secretion upon T3DK infection 
compared to T3DS (Fig. 4). This was most evident after 15 hours post-infection, although the 
effect was already detected after 8 hours. These results were confirmed with α-interferon, 
although levels were reduced compared to those of β-interferon. 
As expected, the monoreassortant harboring solely the T3DK M1 gene in a T3DS 
background induced a higher amount of interferon but not as much as the T3DK virus itself. 
Unexpectedly, the sole presence of T3DK L3 was able to increase significantly interferon 
induction and a combination of M1+L3 was both necessary and sufficient to allow full induction 
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potential as in T3DK. In contrast, the addition of L2 to M1 did not increase interferon levels 
compared to M1 alone. 
It thus appears that, for induction of interferon, the M1+L3 combination is necessary and 
sufficient to reach the full level while L2 has no effect despite its role in sensitivity to 
exogenously added interferon. The strong combined effect of M1+L3 on interferon induction 
probably explains why this virus appears more sensitive to interferon. This was most evident at 
lower exogenous concentrations of interferon, the induced interferon contributing to the overall 




 The importance of the interferon response in the early control of viral infection in various 
contexts appears to be well established. This is supported by the observations that a wide range of 
viruses have actually developed more than one protein, in order to control or limit this response 
within an acceptable limit (Hoffman et al., 2015; Lopez et al., 2015; Weber-Gerlach and 
Weber, 2016). Previous data have suggested that multiple reovirus proteins be involved in the 
control of induction of interferon or sensitivity to the interferon-induced response (Imani and 
Jacobs, 1988; Beattie et al., 1995; Bergeron et al., 1998; Sherry et al., 1998; Zurney et al., 
2009; Irvin et al., 2012; Stebbing et al., 2014; Sandekian and Lemay, 2015a). In the present 
study, it was further established that at least three viral proteins, namely µ2, λ2 and λ1 are 
involved in the control of either induction and/or resistance to interferon. 
  In previous works from the laboratory (Rudd and Lemay 2005; Sandekian and Lemay, 
2015a; Boudreault et al. 2016), it was shown that reovirus interferon sensitivity can be 
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dissociated from interferon induction by a single amino acid substitution in one of the 
methyltransferase domains of the λ2 mRNA capping enzyme. In contrast, another group has 
shown that a single amino acid substitution in the viral µ2 protein increases the interferon 
response, contributing to a concomitant increase in interferon sensitivity (Zurney et al., 2009; 
Irvin et al., 2012). In the present study, the µ2 protein was further shown to affect the production 
of interferon and it was confirmed that this could affect interferon sensitivity. However, the 
higher interferon sensitivity of T3DK compared to T3DS is also due in part to a single amino acid 
difference in λ2, while the higher induction of interferon also relies on a single amino acid 
substitution, but in λ1. Altogether, these various observations further stress that, while both 
phenotypes are interrelated, it is still possible to partly separate induction of interferon production 
by reovirus infection from the sensitivity of the virus to the induced response. A role of both µ2 
and λ2 proteins in interferon sensitivity is also consistent with former classic genetics 
reassortment studies in which genes encoding both proteins were shown to be involved (Sherry 
et al. 1998). 
 The µ2 protein was previously shown to affect interferon response by nuclear 
accumulation of interferon regulatory factor 9 (Zurney et al., 2009). In addition, this protein 
interacts with microtubules and affects the morphology of viral inclusions (Mbisa et al., 2000; 
Parker et al., 2002; Miller et al., 2004; Yin et al., 2004). More recently, it was established that 
this association affects virus assembly and modulates the efficiency of genome assembly, thus 
resulting in differences in the percentage of infectious virions produced upon infection (Ooms et 
al., 2012; Shah et al., 2017). It remains to be determined if this could also independently 
contribute to differences in host-cell response and virus sensitivity to interferon. 
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 The difference in λ2 single amino acid difference between T3DK and T3DS is in the 
protein domain assigned to one of the protein’s methyltransferase activity involved in mRNA 
capping (Reinisch et al. 2000; Bujnicki and Rychlewski 2001), as was also the case in the 
previously isolated interferon sensitive mutant (Sandekian and Lemay, 2015a). The amino acid 
substitutions respectively at positions 504 and 636 are in fact closely located in the 
crystallographic structure of the viral core (PDB1EJ6). In both cases, the substitution is located at 
the extreme outside end of the λ2 turret (Fig. 5); although this position is not in direct contact 
with putative catalytic sites, it is tempting to speculate that it indirectly affects either cap 
methylation or viral mRNA exit. As mentioned by others (Mohamed et al. 2015), it will clearly 
be of interest to further examine the nature of the 5’-end of the viral mRNAs produced by these 
different viruses. The importance of the 2’O-methylation of the first mRNA nucleotide has been 
clearly established in the last few years. For many viruses, abolished or decreased 2’O-
methylation results in increased induction of the response, increased sensitivity to this response, 
or both (Daffis et al., 2011; Zust et al., 2011; Szretter et al., 2012; Habjan et al., 2013; 
Kimura et al., 2013; Ma et al., 2014; Menachery et al., 2014; Chang et al., 2016; Devarkar 
et al., 2017). The 2’O-methylation appears as a major discriminatory factor between cellular and 
foreign mRNA as a target of innate immune response (García-Sastre, 2011; Hyde and 
Diamond, 2015; Leung et al., 2016). 
 The involvement of the λ1 protein in the level of interferon induction came as a surprise 
finding in the course of this study. It remains to be determined if the protein can repress 
interferon signaling in T3DS, a property that is lost in T3DK, or if the T3DK protein positively 
contribute to the interferon induction. Alternatively, a defect in the T3DK protein could affect the 
viral mRNA synthesis or cap structure, thus indirectly contributing to augmenting interferon 
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induction. Although the exact contribution of the two proteins to RNA synthesis and capping is 
not yet completely understood, purified µ2 and λ1 share nucleotide and RNA triphosphatase 
activities (Bisaillon and Lemay, 1997; Bisaillon et al., 1997; Kim et al., 2004). This could 
suggest an impact of one or more of these activities in the production of viral mRNAs as 
interferon inducers. Interestingly, the single amino acid difference between T3DK and T3DS is 
among the 5 amino acids difference previously noted between T3D and serotype 1 T1L virus. 
These differences are affecting NTPase activity associated with the viral core and synthesis of the 
viral mRNA and/or cap structure (Harrison et al., 1999). Recently, viral-triggered ATP release 
by vesicular stomatitis virus was found to be associated with interferon induction (Zhang et al., 
2017), the relative activity of a viral ATPase is thus potentially relevant in this context and 
deserves further study. 
 Altogether, the data reported herein demonstrate that different reovirus proteins, by 
themselves or in combinations, could affect either induction of interferon or sensitivity of a given 
virus to the interferon response. It should thus be possible to combine mutant forms of different 
viral proteins in order to modulate both the induction of interferon and/or interferon response, 
and sensitivity to the response. As previously mentioned, this could well be of importance to 
optimize oncolytic viral strains to different tumor cell types (Randall and Goodbourn, 2008; 
Naik and Russell, 2009; Kaufman et al., 2015; Vaha-Koskela and Hinkkanen, 2014; 
Ebrahimi et al., 2017). Virus replication in the absence of exogenously added interferon was 
also briefly examined. As somehow expected it was noticed that the T3DK virus has an 
approximately three to fivefold lower viral titers than T3DS at both 24 and 48-hour post-infection 
in conditions allowing viral propagation (Fig. S1). Interestingly both the interferon-sensitive and 
interferon-inducing reassortants exhibited essentially the same replicative phenotype as T3DK. 
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Further study will be needed to establish the importance of both phenotypes in viral replication in 
different cell types and in vivo using these viruses. 
Overall, the results obtained in the present study also further stress that one should be very 
careful while interpreting previous data using virus stocks from different laboratories. The advent 
of plasmid-based reverse genetics (Kobayashi et al. 2007, 2010), and recent progress resulting in 
increased efficiency of the procedure (Eaton et al. 2017; Kanai et al. 2017) should now allow 
all laboratories to work with well genetically characterized viruses in order to avoid possible 




 This work was supported by an operating (discovery) grant from the Natural Sciences and 
Engineering Research Council of Canada (NSERC) to G.L. Partial financial support to D.L. was 




Beattie, E., Denzler, K.L., Tartaglia, J., Perkus, M.E., Paoletti, E., Jacobs, B.L., 1995. Reversal of 
the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the 
reovirus S4 gene. J. Virol. 69, 499–505. 
Berard, A.R., Severini, A., Coombs, K.M., 2015. Comparative proteomic analyses of two 
reovirus T3D subtypes and comparison to T1L identifies multiple novel proteins in key 
cellular pathogenic pathways. Proteomics 15, 2113–2135. 
Bergeron, J., Mabrouk, T., Garzon, S., Lemay, G., 1998. Characterization of the thermosensitive 
ts453 reovirus mutant: increased dsRNA binding of σ3 protein correlates with interferon 
resistance. Virology 246, 199–210. 
Bisaillon, M., Lemay, G., 1997. Characterization of the reovirus λ1 protein RNA 5′-
triphosphatase activity. J. Biol. Chem. 272, 29954–29957. 
Bisaillon, M., Bergeron, J., Lemay, G., 1997. Characterization of the nucleoside triphosphate 
phosphohydrolase and helicase activities of the reovirus λ1 protein. J. Biol. Chem. 272, 
18298–18303. 
Black, A.J., Morris, D.G., 2012. Clinical trials involving the oncolytic virus, reovirus: Ready for 
prime time? Expert Rev. Clin. Pharmacol. 5, 517–520. 
Boudreault, S., Martenon-Brodeur, C., Caron, M., Garant, J.-M., Tremblay, M.-P., Armero, V.E. 
S., Durand, M., Lapointe, E., Thibault, P., Tremblay-Létourneau, M., Perreault, J.-P., 
Scott, M.S., Lemay, G., Bisaillon, M., 2016. Global profiling of the cellular alternative 
RNA splicing landscape during virus-host interactions. PLoS ONE 11, e0161914–21.  
	18	
Brochu-Lafontaine, V., Lemay, G., 2012. Addition of exogenous polypeptides on the mammalian 
reovirus outer capsid using reverse genetics. J. Virol. Methods 179, 342–350. 
Buchholz, U.J., Finke, S., Conzelmann, K.-K. 1999. Generation of bovine respiratory syncytial 
virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue 
culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. 
Virol. 73, 251–259. 
Bujnicki, J.M., Rychlewski, L., 2001. Reassignment of specificities of two cap methyltransferase 
domains in the reovirus λ2 protein. Genome Biol. 2, research0038.1–0038.6. 
Chakrabarty, R., Tran, H., Selvaggi, G., Hagerman, A., Thompson, B., Coffey, M., 2015. The 
oncolytic virus, pelareorep, as a novel anticancer agent: a review. Invest. New Drugs 33, 
761–774. 
Chang, D.C., Hoang, L.T., Naim, A.N.M., Dong, H., Schreiber, M.J., Hibberd, M.L., Tan, 
M.J.A., Shi, P.-Y., 2016. Evasion of early innate immune response by 2′-O-methylation of 
dengue genomic RNA. Virology 499, 259–266. 
Clements, D., Helson, E., Gujar, S.A., Lee, P.W.K., 2014. Reovirus in cancer therapy: an 
evidence-based review. Oncolytic Virother. 3, 69–82. 
Coffey, C.M., Sheh, A., Kim, I.S., Chandran, K., Nibert, M.L., Parker, J.S.L., 2006. Reovirus 
outer capsid protein micro1 induces apoptosis and associates with lipid droplets, 
endoplasmic reticulum, and mitochondria. J. Virol. 80, 8422–8438. 
Daffis, S., Szretter, K.J., Schriewer, J., Li, J., Youn, S., Errett, J., Lin, T.-Y., Schneller, S., Zust, 
R., Dong, H., Thiel, V., Sen, G.C., Fensterl, V., Klimstra, W.B., Pierson, T.C., Buller, 
R.M., Gale, M., Shi, P.-Y., Diamond, M.S., 2011. 2’-O methylation of the viral mRNA 
cap evades host restriction by IFIT family members. Nature 468, 452–456. 
	19	
Danis, C., Lemay, G., 1993. Protein synthesis in different cell lines infected with orthoreovirus 
serotype 3: inhibition of host-cell protein synthesis correlates with accelerated viral 
multiplication and cell killing. Biochem. Cell Biol. 71, 81–85.	
Devarkar, S.C., Wang, C., Miller, M.T., Ramanathan, A., Jiang, F., Khan, A.G., Patel, S.S., 
Marcotrigiano, J., 2016. Structural basis for m7G recognition and 2′-O-methyl 
discrimination in capped RNAs by the innate immune receptor RIG-I. Proc. Natl. Acad. 
Sci. U.S.A. 113, 596–601. 
Eaton, H.E., Kobayashi, T., Dermody, T.S., Johnston, R.N., Jais, P.H., Shmulevitz, M., 2017. 
African swine fever virus NP868R capping enzyme promotes reovirus rescue during 
reverse genetics by promoting reovirus protein expression, virion assembly, and RNA 
incorporation into infectious virions. J. Virol. 91, e02416–16. 
Ebrahimi, S., Ghorbani, E., Khazaei, M., Avan, A., Ryzhikov, M., Azadmanesh, K., Hassanian, 
S.M., 2017. Interferon-mediated tumor resistance to oncolytic virotherapy. J. Cell. 
Biochem. 118, 1994–1999. 
García-Sastre, A., 2011. 2 methylate or not 2 methylate: viral evasion of the type I interferon 
response. Nat. Immunol. 12, 114–115. 
Habjan, M., Hubel, P., Lacerda, L., Benda, C., Holze, C., Eberl, C.H., Mann, A., Kindler, E., Gil-
Cruz, C., Ziebuhr, J., Thiel, V., Pichlmair, A., 2013. Sequestration by IFIT1 impairs 
translation of 2’O-unmethylated capped RNA. PLoS Pathog. 9, e1003663. 
Harrington, K.J., Vile, R.G., Melcher, A., Chester, J., Pandha, H.S., 2010. Clinical trials with 
oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics. 
Cytokine Growth Factor Rev. 21, 91–98. 
	20	
Harrison, S.J., Farsetta, D.L., Kim, J., Noble, S., Broering, T.J., Nibert, M.L., 1999. Mammalian 
reovirus L3 gene sequences and evidence for a distinct amino-terminal region of the λ1 
protein. Virology 258, 54–64. 
Hoffmann, H.-H., Schneider, W.M., Rice, C.M., 2015. Interferons and viruses: an evolutionary 
arms race of molecular interactions. Trends Immunol 36, 124–138. 
Hyde, J.L., Diamond, M.S., 2015. Innate immune restriction and antagonism of viral RNA 
lacking 2’-O methylation. Virology 479–480, 66–74. 
Ilkow, C.S., Swift, S.L., Bell, J.C., Diallo, J.-S., 2014. From scourge to cure: tumour-selective 
viral pathogenesis as a new strategy against cancer. PLoS Pathog. 10, e1003836. 
Imani, F., Jacobs, B.L. 1988. Inhibitory activity for the interferon-induced protein kinase is 
associated with the reovirus serotype 1 σ3 protein. Proc. Natl. Acad. Sci. U.S.A. 85, 
7887–7891. 
Irvin, S.C., Zurney, J., Ooms, L.S., Chappell, J.D., Dermody, T.S., Sherry, B., 2012. A single-
amino-acid polymorphism in reovirus protein µ2 determines repression of interferon 
signaling and modulates myocarditis. J. Virol. 86, 2302–2311. 
Kanai, Y., Komoto, S., Kawagishi, T., Nouda, R., Nagasawa, N., Onishi, M., Matsuura, Y., 
Taniguchi, K., Kobayashi, T., 2017. Entirely plasmid-based reverse genetics system for 
rotaviruses. Proc. Natl. Acad. U.S.A. 114, 2349–2354.  
Kaufman, H.L., Kohlhapp, F.J., Zloza, A., 2015. Oncolytic viruses: a new class of 
immunotherapy drugs. Nat. Rev. Drug Discov. 14, 642–662. 
Kelly, K., Nawrocki, S., Mita, A., Coffey, M., Giles, F.J., Mita, M., 2009. Reovirus-based 
therapy for cancer. Expert Opin. Biol. Ther. 9, 817–830. 
	21	
Kemp, V., Hoeben, R., van den Wollenberg, D., 2016. Exploring reovirus plasticity for 
improving its use as oncolytic virus. Viruses 8, 4–16. 
Kim, J., Parker, J.S.L., Murray, K.E., Nibert, M.L., 2004. Nucleoside and RNA triphosphatase 
activities of orthoreovirus transcriptase cofactor µ2. J. Biol. Chem. 279, 4394–4403. 
Kimura, T., Katoh, H., Kayama, H., Saiga, H., Okuyama, M., Okamoto, T., Umemoto, E., 
Matsuura, Y., Yamamoto, M., Takeda, K., 2013. Ifit1 inhibits Japanese encephalitis virus 
replication through binding to 5’ capped 2’-O unmethylated RNA. J. Virol. 87, 9997–
10003. 
Kobayashi, T., Antar, A.A., Boehme, K.W., Danthi, P., Eby, E.A., Guglielmi, K.M., Holm, G.H., 
Johnson, E.M., Maginnis, M.S., Naik, S., Skelton, W.B., Wetzel, J.D., Wilson, G.J., 
Chappell, J.D., Dermody, T.S., 2007. A plasmid-based reverse genetics system for animal 
double-stranded RNA viruses. Cell Host Microbe 1, 147–157. 
Kobayashi, T., Ooms, L.S., Ikizler, M., Chappell, J.D., Dermody, T.S., 2010. An improved 
reverse genetics system for mammalian orthoreoviruses. Virology 398, 194–200. 
Lemay, G., 2011. Inverse genetics in the study of reoviruses: progress, obstacles and future 
developments (In French). Virologie 15, 53–62. 
Leung, D.W., Amarasinghe, G.K., 2016. When your cap matters: structural insights into self vs 
non-self recognition of 5′ RNA by immunomodulatory host proteins. Curr. Opin. Struct. 
Biol. 36, 133–141. 
López, S., Sánchez-Tacuba, L., Moreno, J., Arias, C.F., 2015. Rotavirus strategies against the 
innate antiviral system. Ann. Rev. Virol. 3, 591–609. 
	22	
Ma, Y., Wei, Y., Zhang, X., Zhang, Y., Cai, H., Zhu, Y., Shilo, K., Oglesbee, M., Krakowka, S., 
Whelan, S.P.J., Li, J., Lyles, D.S., 2014. mRNA cap methylation influences pathogenesis 
of vesicular stomatitis virus in vivo. J. Virol. 88, 2913–2926. 
Mbisa, J.L., Becker, M.M., Zou, S., Dermody, T.S., Brown, E.G., 2000. Reovirus µ2 protein 
determines strain-specific differences in the rate of viral inclusion formation in L929 
cells. Virology 272, 16–26. 
Menachery, V.D., Yount, B.L., Josset, L., Gralinski, L.E., Scobey, T., Agnihothram, S., Katze, 
M.G., Baric, R.S., 2014. Attenuation and restoration of severe acute respiratory syndrome 
coronavirus mutant lacking 2’-O-methyltransferase activity. J. Virol. 88, 4251–4264. 
Miest, T.S., Cattaneo, R., 2014. New viruses for cancer therapy: meeting clinical needs. Nat. Rev. 
Microbiol. 12, 23–34. 
Miller, C.L., Parker, J.S.L., Dinoso, J.B., Piggott, C.D.S., Perron, M.J., Nibert, M. L., 2004. 
Increased ubiquitination and other covariant phenotypes attributed to a strain- and 
temperature-dependent defect of reovirus core protein µ2. J. Virol. 78, 10291–10302. 
Mohamed, A., Johnston, R., Shmulevitz, M., 2015. Potential for improving potency and 
specificity of reovirus oncolysis with next-generation reovirus variants. Viruses 7, 6251–
6278. 
Naik, S., Russell, S.J., 2009. Engineering oncolytic viruses to exploit tumor specific defects in 
innate immune signaling pathways. Expert Opin. Biol. Ther. 9, 1163–1176. 
Nygaard, R.M., Lahti, L., Boehme, K.W., Ikizler, M., Doyle, J.D., Dermody, T.S., Schiff, L.A., 
2013. Genetic determinants of reovirus pathogenesis in a murine model of respiratory 
infection. J. Virol. 87, 9279–9289. 
	23	
Ooms, L.S., Jerome, W.G., Dermody, T.S., Chappell, J.D., 2012. Reovirus replication protein µ2 
influences cell tropism by promoting particle assembly within viral inclusions. J. Virol. 
86, 10979–10987. 
Parker, J.S.L., Broering, T.J., Kim, J., Higgins, D.E., Nibert, M.L., 2002. Reovirus core protein 
µ2 determines the filamentous morphology of viral inclusion bodies by interacting with 
and stabilizing microtubules. J. Virol. 76, 4483–4496.  
Pikor, L.A., Bell, J.C., Diallo, J.-S., 2015. Oncolytic viruses: exploiting cancer’s deal with the 
devil. Trends Cancer 4, 266–277. 
Randall, R.E., Goodbourn, S. 2008. Interferons and viruses: an interplay between induction, 
signaling, antiviral responses and virus countermeasures. J. Gen. Virol. 89, 1–47. 
Reinisch, K.M., Nibert, M.L., Harrison, S.C., 2000. Structure of the reovirus core at 3.6 A 
resolution. Nature 404, 960–967. 
Rudd, P., Lemay, G., 2005. Correlation between interferon sensitivity of reovirus isolates and 
ability to discriminate between normal and Ras-transformed cells. J. Gen. Virol. 86, 
1489–1497. 
Sandekian, V., Lemay, G., 2015a. A single amino acid substitution in the mRNA capping 
enzyme λ2 of a mammalian orthoreovirus mutant increases interferon sensitivity. 
Virology, 483, 229–235. 
Sandekian, V., Lemay, G., 2015b. Amino acids substitutions in σ1 and µ1 outer capsid proteins 
of a Vero cell-adapted mammalian orthoreovirus are required for optimal virus binding 
and disassembly. Virus Res. 196, 20–29.  
	24	
Sandekian, V., Lim, D., Prud’homme, P., Lemay, G., 2013. Transient high level mammalian 
reovirus replication in a bat epithelial cell line occurs without cytopathic effect. Virus 
Res. 173, 327–335. 
Shah, P.N.M., Stanifer, M.L., Höhn, K., Engel, U., Haselmann, U., Bartenschlager, R., 
Kräusslich, H.-G., Krijnse-Locker, J., Boulant, S., 2017. Genome packaging of reovirus is 
mediated by the scaffolding property of the microtubule network. Cell. Microbiol. 
e12765–44. 
Sherry, B., Torres, J., Blum, M.A., 1998. Reovirus induction of and sensitivity to beta interferon 
in cardiac myocyte cultures correlate with induction of myocarditis and are determined by 
viral core proteins. J. Virol. 72, 1314–1323. 
Shmulevitz, M., Pan, L.-Z., Garant, K., Pan, D., Lee, P.W.K., 2010. Oncogenic Ras promotes 
reovirus spread by suppressing IFN-β production through negative regulation of RIG-I 
signaling. Cancer Res. 70, 4912–4921.  
Stebbing, R.E., Irvin, S.C., Rivera-Serrano, E.E., Boehme, K.W., Ikizler, M., Yoder, J.A., 
Dermody, T.S., Sherry, B., Lyles, D.S., 2014. An ITAM in a nonenveloped virus 
regulates activation of NF-κB, induction of beta interferon, and viral spread. J. Virol. 88, 
2572–2583. 
Strong, J.E., Coffey, M.C., Tang, D., Sabinin, P., Lee, P.W., 1998. The molecular basis of viral 
oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 17, 3351–3362. 
Stuart, J.D., Philips, M.B., Boehme, K.W., 2017. Reverse genetics for mammalian orthoreovirus, 
in: Perez, D.R., (Ed.), Reverse genetics of RNA viruses: Methods and protocols. Humana 
Press, pp. 1–10. 
Szretter, K.J., Daniels, B.P., Cho, H., Gainey, M.D., Yokoyama, W.M., Gale, M., Virgin, H.W., 
	25	
Klein, R.S., Sen, G.C., Diamond, M.S., 2012. 2′-O methylation of the viral mRNA cap by 
west Nile virus evades Ifit1-dependent and -independent mechanisms of host restriction in 
vivo. PLoS Pathog. 8, e1002698–13. 
Turnbull, S., West, E., Scott, K., Appleton, E., Melcher, A., Ralph, C., 2015. Evidence for 
oncolytic virotherapy: where have we got to and where are we going? Viruses 7, 6291–
6312. 
Vaha-Koskela, M., Hinkkanen, A., 2014. Tumor restrictions to oncolytic virus. Biomedicines 2, 
163–194. 
van den Hengel, S.K., Dautzenberg I.J.C., van den Wollenberg, D.J.M., Sillevis Smitt, P.A.E., 
Hoeben, R.C., 2013. Genetic modification in mammalian orthoreoviruses, in: Bridgen, A., 
(Ed.), Reverse genetics of RNA viruses: Applications and perspectives. John Wiley & 
Sons Ltd., Chichester, West Sussex, UK, pp. 289–317. 
van den Wollenberg, D.J.M., Dautzenberg, I.J.C., van den Hengel, S.K., Cramer, S.J., de Groot, 
R.J., Hoeben, R.C., 2012. Isolation of reovirus T3D mutants capable of infecting human 
tumor cells independent of junction adhesion molecule-A. PLoS One 7, e48064. 
Virgin, H.W., Mann, M.A., Fields, B.N., Tyler, K.L., 1991. Monoclonal antibodies to reovirus 
reveal structure/function relationships between capsid proteins and genetics of 
susceptibility to antibody action. J. Virol. 65, 6772–6781. 
Weber-Gerlach, M., Weber, F., 2016. To conquer the host, influenza virus is packing it in: 
interferon-antagonistic strategies beyond NS1. J. Virol. 90, 8389–8394. 
Yin, P., Keirstead, N.D., Broering, T.J., Arnold, MM., Parker, J. S., Nibert, M.L., Coombs, K.M., 
2004. Comparisons of the M1 genome segments and encoded µ2 proteins of different 
reovirus isolates. Virol. J. 1, 6. 
	26	
Zhang, C., He, H., Wang, L., Zhang, N., Huang, H., Xiong, Q., Yan, Y., Wu, N., Ren, H., Han, 
H., Liu, M., Qian, M., Du, B., 2017. Virus-triggered ATP release limits viral replication 
through facilitating IFN-β production in a P2X7-dependent manner. J. Immunol. 199, 
1372–1381. 
Zurney, J., Kobayashi, T., Holm, G.H., Dermody, T.S., Sherry, B., 2009. Reovirus µ2 protein 
inhibits interferon signaling through a novel mechanism involving nuclear accumulation 
of interferon regulatory factor 9. J. Virol. 83, 2178–2187. 
Zust, R., Cervantes-Barragan, L., Habjan, M., Maier, R., Neuman, B.W., Ziebuhr, J., Szretter, 
K.J., Baker, S.C., Barchet, W., Diamond, M.S., Siddell, S.G., Ludewig, B., Thiel, V., 
2011. Ribose 2’-O-methylation provides a molecular signature for the distinction of self 





Fig. 1. Interferon sensitivity of virus monoreassortants. Genes from reovirus reverse genetics 
virus T3DK were separately introduced in the genetic background of the T3DS laboratory virus 
stock using reverse genetics, as described in the text. Virus titers in the absence or presence of 
200 IU/ml of ß-interferon were compared, as described in the text. Fold reductions in titers due to 
interferon presence are presented on a logarithmic scale. 
 
Fig. 2. Interferon sensitivity of multiple reassortants. Viruses harboring various gene 
combinations of T3DK in the T3DS background were compared with viruses harboring the full 
gene complement of either parental virus. Results are presented as fold decrease in the presence 
of interferon, on a logarithmic scale, as in figure 1. Error bars indicate the highest value obtained 
in cases where two independent experiments were performed. 
 
Fig.3. Sensitivity of double reassortant viruses to different interferon concentrations. The double 
reassortant viruses harboring M1+L2 or M1+L3 of T3DK in the T3DS background were examined 
by the interferon dilution assay. The average of three independent experiments is presented as the 
relative cell destruction, compared to control mock-infected cells, determined by optical density 
of methylene blue stain, as described in Materials and methods (section 2.3). 
 
Fig. 4. Interferon induction by viral reassortants. L929 cells were infected at a MOI of 20 TCID50 
units per cell. Infected cells media were recovered after 8 or after 15 hours post-infection and 
directly used in commercial ELISA assay, as described in Materials and methods, for either β-
	28	
interferon (left panel) or α-interferon (right panel) quantitation. Results are presented as the 
average of two independent experiments with error bars representing the standard error of the 
mean. 
 
Fig.5. Positions of λ2 amino acid substitutions on the crystal structure (PDB1EJ6). The position 
of the previously described substitution in the interferon-sensitive P4L-12 virus (amino acid 636) 
is indicated as a green sphere while the amino acid difference between T3DS and T3DK (amino 
acid 504) is indicated as a red sphere. The methyltransferase domain (amino acids 434 to 691) is 
in cyan. The image, at left, shows a side view of the protein, the virion-anchored region being on 
the left. The image at right shows a top view of the molecule from the outside of the virion. 
Images were obtained using the PyMOL Molecular Graphics System Version 2.0.0. 
 
Fig.S1. Replicative ability of parental and reassortant viruses. The two parental viruses T3DS and 
T3DK, as well as the interferon-sensitive reassortant (harboring the M1+L2 gene of T3DK in the 
T3DS background) and interferon-inducing reassortant (harboring the M1+L3 gene of T3DK in 
the T3DS background), were examined for their replicative ability. Each virus was used to infect 
L929 cells at a multiplication of infection of 0.05 TCID50 unit per cell and cells incubated for 
either 24 or 48 hours. Cells and tissue culture were recovered, submitted to three cycles of freeze-
thaw (–80 °C to room temperature) and infectious titers determined by TCID50 on L929 cells. 
Results are presented as the average of two experiments with error bars representing the standard 
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Accession numbers for T3DS are KP208804 to KP208813; accession number for T3DK are 
EF494435 to EF494444. 
  






